Bayer collaborates on AI drug discovery, shares reflect cautious analyst stance
22.06.2026 - 17:33:31 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 17:25.
Bayer (DE000BAY0017) adds a new technology partner for research as it cooperates with US start-up Iambic in the use of artificial intelligence for early drug discovery, according to a report timestamped 22 June on MarketScreener referencing Dow Jones Newswires and covering the DAX member's latest moves on Xetra. The cooperation gives Bayer access to Iambic's AI platform aimed at identifying and optimizing novel compounds for complex disease targets, expanding earlier work in cardiovascular and immunology drug projects.
Bayer and Iambic expand AI research
The MarketScreener note states that Bayer is working with Iambic on AI-based small-molecule discovery, building on earlier collaborations that focused on precision oncology and cardiovascular indications. The San Diego-based start-up contributes generative AI models and structure-based design tools, while Bayer brings disease biology expertise and global clinical development capabilities.
Iambic, which has also disclosed partnerships with other large pharma groups, targets faster lead-optimization cycles and a higher success rate in preclinical candidate selection, according to previous company statements cited by analyst reports. For Bayer, the cooperation fits the ongoing R&D restructuring under CEO Bill Anderson, who has emphasized sharper portfolio focus and external innovation deals since 2023.
Analyst views remain mixed but slightly positive
Consensus data compiled by MarketScreener show that 23 analysts currently cover Bayer, with roughly half of them rating the stock as a Buy or equivalent and the remainder mostly on Hold. The average 12-month price target stands in the low-50 euro range, compared with a current quotation in the high-30s, implying an upside potential from today's trading levels but with significant execution and litigation risks.
Recent individual actions highlight the divided view: UBS reiterated a Buy rating with a 52 euro target in mid-May, citing the potential value of the pharma and crop science franchises despite the glyphosate litigation overhang. By contrast, Sadif Investment Analytics downgraded Bayer to Sell on 19 June in a quantitative-based assessment that flagged balance-sheet strain and legal uncertainty, according to the same MarketScreener overview.
All news and analysis on the Bayer shares
Price data, ad-hoc releases and further analyst commentary on Bayer can be found in the dedicated topic area on ad-hoc-news.de and on the group’s Investor Relations pages.
Pharma and crop science products
Bayer generates a major share of its revenue with prescription drugs such as the anticoagulant Xarelto and the eye medicine Eylea, alongside a large crop science division that includes herbicides and seeds for farmers worldwide. Consumer health brands such as Aspirin and Bepanthen add further, more stable over-the-counter income streams.
Where the Bayer shares trade today
The Bayer shares (DE000BAY0017) trade on Xetra at around 37.40 euros in Monday afternoon dealing, based on data points from Finanznachrichten and MarketScreener for the DAX-listed stock.
Key data on the Bayer shares
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of 2026-06-22, 15:15): 37.40 EUR
- Market cap: around 36 billion EUR (as of 2026-06-22)
- Sector / industry: Pharmaceuticals, Biotechnology & Life Sciences
- Index membership: DAX, Euro Stoxx 50, Stoxx Europe 600
- Next earnings date: 2026-08-07
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical data and analyst assessments do not guarantee future performance. Readers should conduct their own research or consult a licensed financial advisor before making investment decisions.
